Page 52 - Read Online

Page 10 of 11 Chávez-Castillo et al. Vessel Plus 2018;2:6 I http://dx.doi.org/10.20517/2574-1209.2018.02

depression. Pharmacopsychiatry 1991;24:62-7.
65. Michelson D, Amsterdam JD, Quitkin FM, Reimherr FW, Rosenbaum JF, Zajecka J, Sundell KL, Kim Y, Beasley CM Jr. Changes in
weight due to a 1-year trial of fluoxetine. Am J Psychiatry 1999;156:1170-6.
66. Olguner Eker Ö, Özsoy S, Eker B, Doğan H. Metabolic effects of antidepressant treatment. Noro Psikiyatr Ars 2017;54:49-56.
67. Fava M, Judge R, Hoog SL, Nilsson ME, Koke SC. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in
weight with long-term treatment. J Clin Psychiatry 2000;61:863-7.
68. Mansoor B, Rengasamy M, Hilton R, Porta G, He J, Spirito A, Emslie GJ, Mayes TL, Clarke G, Wagner KD, Shamseddeen W,
Birmaher B, Ryan N, Brent D. The bidirectional relationship between body mass index and treatment outcome in adolescents with
treatment-resistant depression. J Child Adolesc Psychopharmacol 2013;23:458-67.
69. Emslie GJ, Heiligenstein JH, Hoog SL, Wagner KD, Findling RL, McCracken JT, Nilsson ME, Jacobson JG. Fluoxetine treatment for
prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study. J Am Acad Child Adolesc
Psychiatry 2004;43:1397-405.
70. Nilsson M, Joliat M, Miner C, Brown E, Heiligenstein J. Safety of subchronic treatment with fluoxetine for major depressive disorder in
children and adolescents. J Child Adolesc Psychopharmacol 2004;14:412-7.
71. Calarge CA, Mills JA, Janz KF, Burns TL, Coryell WH, Zemel BS. Body composition in adolescents during treatment with selective
serotonin reuptake inhibitors. Pediatrics 2017;140:e20163943.
72. Gibson-Smith D, Bot M, Milaneschi Y, Twisk J, Visser M, Brouwer IA, Penninx BW. Major depressive disorder, antidepressant use, and
subsequent 2-year weight change patterns in the Netherlands study of depression and anxiety. J Clin Psychiatry 2015;77:e144-51.
73. McIntyre R, Soczynska J, Konarski J, Kennedy S. The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis
and mechanisms. Expert Opin Drug Saf 2005;5:157-68.
74. Derijks H, Meyboom R, Heerdink E, De Koning F, Janknegt R, Lindquist M, Egberts AC. The association between antidepressant use
and disturbances in glucose homeostasis: evidence from spontaneous reports. Eur J Clin Pharmacol 2008;64:531-8.
75. Andersohn F, Schade R, Suissa S, Garbe E. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus.
Am J Psychiatry 2009;166:591-8.
76. Goodnick PJ, Kumar A, Henry JH, Buki VM, Goldberg RB. Sertraline in coexisting major depression and diabetes mellitus.
Psychopharmacol Bull 1997;33:261-4.
77. Dhavale HS, Panikkar V, Jadhav BS, Ghulghule M, Agari AD. Depression and diabetes: impact of antidepressant medications on
glycaemic control. J Assoc Physicians India 2013;61:896-9.
78. Maheux P, Ducros F, Bourque J, Garon J, Chiasson JL. Fluoxetine improves insulin sensitivity in obese patients with non-insulin-
dependent diabetes mellitus independently of weight loss. Int J Obes Relat Metab Disord 1997;21:97-102.
79. Kauffman RP, Castracane VD, White DL, Baldock SD, Owens R. Impact of the selective serotonin reuptake inhibitor citalopram on
insulin sensitivity, leptin and basal cortisol secretion in depressed and non-depressed euglycemic women of reproductive age. Gynecol
Endocrinol 2005;21:129-37.
80. Weber-Hamann B, Gilles M, Lederbogen F, Heuser I, Deuschle M. Improved insulin sensitivity in 80 nondiabetic patients with MDD
after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine. J Clin Psychiatry 2006;67:1856-61.
81. Paile-Hyvärinen M, Wahlbeck K, Eriksson JG. Quality of life and metabolic status in mildly depressed women with type 2 diabetes
treated with paroxetine: a single-blind randomised placebo controlled trial. BMC Fam Pract 2003;4:7.
82. Yoon JM, Cho EG, Lee HK, Park SM. Antidepressant use and diabetes mellitus risk: a meta-analysis. Korean J Fam Med 2013;34:228-40.
83. Yosmaoğlu A, Fıstıkcı N, Keyvan A, Hacıoğlu M, Erten E, Saatçioğlu Ö, Kora K. Correlation of selective serotonin re-uptake inhibitor
use with weight gain and metabolic parameters. Anadolu Psikiyatri Derg 2013;14:245-51.
84. Gabriel A. Changes in plasma cholesterol in mood disorder patients: does treatment make a difference? J Affect Disord 2007;99:273-8.
85. Serodio KJ, Ardern CI, Rotondi M, Kuk J. Tricyclic and SSRI usage influences the association between BMI and health risk factors.
Clin Obes 2014;4:296-302.
86. Deisenhammer EA, Kramer-Reinstadler K, Liensberger D, Kemmler G, Hinterhuber H, Fleischhacker WW. No evidence for an
association between serum cholesterol and the course of depression and suicidality. Psychiatry Res 2004;121:253-61.
87. Ma Y, Balasubramanian R, Pagoto SL, Schneider KL, Hebert JR, Phillips LS, Goveas JS, Culver AL, Olendzki BC, Beck J, Smoller JW,
Sepavich DM, Ockene JK, Uebelacker L, Zorn M, Liu S. Relations of depressive symptoms and antidepressant use to body mass index
and selected biomarkers for diabetes and cardiovascular disease. Am J Public Health 2013;103:e34-43.
88. Herran A, Ramirez ML, Carrera M, Garcia-Unzueta MT, Sierra-Biddle D, Rodríguez-Cabo B, Ayestarán A, Hoyuela F, Vázquez-
Barquero JL. Panic disorder, treatment with selective serotonin reuptake inhibitors, and cholesterol levels. J Clin Psychopharmacol
2006;26:538-40.
89. Wei F, Crain AL, Whitebird RR, Godlevsky OV, O’Connor PJ. Effects of paroxetine and sertraline on low-density lipoprotein
cholesterol: an observational cohort study. CNS Drugs 2009;23:857-65.
90. Beyazyüz M, Albayrak Y, Eğilmez OB, Albayrak N, Beyazyüz E. Relationship between SSRIs and metabolic syndrome abnormalities
in patients with generalized anxiety disorder: a prospective study. Psychiatry Investig 2013;10:148-54.
91. Teitelbaum M. Severe hypertriglyceridemia secondary to venlafaxine and fluoxetine. Psychosomatics 2001;42:440-1.
92. Teitelbaum M. Severe and moderate hypertriglyceridemia secondary to citalopram and fluoxetine. Psychosomatics 2000;41:448-9.
93. Kesim M, Tiryaki A, Kadioglu M, Muci E, Kalyoncu NI, Yaris E. The effects of sertraline on blood lipids, glucose, insulin and HBA1C
levels: a prospective clinical trial on depressive patients. J Res Med Sci 2011;16:1525-31.
94. Khawaja I, Feinstein R. Cardiovascular effects of selective serotonin reuptake inhibitors and other novel antidepressants. Heart Dis